Russia is a very well respected clinical trial country, far above any country in Europe to include the UK, Germany, France, and Italy based on trial infractions going against FDA protocols.
I think the cause for the heavy sway to Russia was a big patient base in Russia and a small base in the US, plus I think Russia worked harder (just IMO) than the USA hospitals in recruiting. I am hoping Russia was able to get patients with variant infections and also hope they got some patients with the black fungus as well so that we could get some preliminary data on whether B was able to nullify that condition as well as the CV19 virus.
Have to admit I don't put full trust in the US medical agencies running the approval system (too much payola and BP influence IMO) and am happy as a clam that Russia took the heavy lifting and got it done in a short time period.
Believe in the long run this will be a very advantageous outcome, Russia conducting the vast majority of the trial, and IPIX and Brilacidin for CV19 will heartily benefit from it.
Also hope the last couple of days of trading have shown the light to many that cheering little movement upwards in the share price is still far too early to stick and trading is still completely controlled by those agents using computer trading to yo-yo or crumble the stock price.
Our day WILL come, it will just be August at the very earliest IMO.
News 
Market Data 
Discover 
AI
